Feasibility of redo-TAVI in self-expanding Evolut valves: a CT analysis from the Evolut Low Risk Trial substudy

EuroIntervention, Год журнала: 2023, Номер 19(4), С. e330 - e339

Опубликована: Июль 1, 2023

Transcatheter aortic valve implantation in an existing transcatheter (redo-TAVI) pins the index leaflets open position (neoskirt), which can cause coronary flow compromise and limit access. Whether anatomy may preclude redo-TAVI self-expanding Evolut valves is unknown.

Язык: Английский

---

5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis

Journal of the American College of Cardiology, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years. Outcomes 5 years have not been reported. This study sought evaluate 5-year clinical and hemodynamic outcomes with TAVR vs in patients from trial. We randomly assigned low-risk severe stenosis surgery. a composite stroke. Secondary endpoints included clinical, echocardiographic, quality-of-life through A total 1,414 underwent an attempted implant (n = 730 TAVR, n 684 surgery). mean age 74 (range 51-88 years), women accounted 35% patients. At Kaplan-Meier estimate 15.5% group 16.4% (P 0.47). estimates groups were 13.5% 14.9% 0.39) 3.6% 4.0% 0.57). Cardiovascular 7.2% 9.3% 0.15). Noncardiovascular 6.8% 6.2% 0.73). site-level vital status sweep performed who lost follow-up withdrew study. With addition these patients, rate undergoing 14.7% 15.2% 0.74). Over years, reintervention 3.3% 2.5% 0.44). sustained improvement quality life observed both treatment arms Kansas City Cardiomyopathy Questionnaire summary score 88.3 ± 15.8 88.5 treated either had comparable rates Valve durability performance excellent arms. midterm evaluation reinforces position as low surgical risk (Medtronic Transcatheter Aortic Replacement Patients; NCT02701283).

Язык: Английский

---

National Variability in Pacemaker Implantation Rate Following TAVR

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2024, Номер 17(3), С. 391 - 401

Опубликована: Фев. 1, 2024

Язык: Английский

---

Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients: An Updated Metanalysis of Extended Follow-Up Randomized Controlled Trials

The American Journal of Cardiology, Год журнала: 2024, Номер 224, С. 56 - 64

Опубликована: Май 8, 2024

Язык: Английский

---

3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2024, Номер 17(14), С. 1667 - 1675

Опубликована: Июль 1, 2024

Язык: Английский

---

Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study

Circulation Cardiovascular Interventions, Год журнала: 2023, Номер 16(11)

Опубликована: Ноя. 1, 2023

BACKGROUND: Coronary accessibility following redo–transcatheter aortic valve replacement (redo-TAVR) is increasingly important, particularly in younger low-risk patients. This study aimed to predict coronary after simulated Sapien-3 balloon-expandable implantation within an Evolut supra-annular, self-expanding using pre-TAVR computed tomography (CT) imaging. METHODS: A total of 219 CT scans from the Low-Risk substudy were analyzed. Virtual and valves sized CT-based diameters. Two initial implant depths analyzed, 3 5 mm. was evaluated for 2 positions: outflow at node 4 5. RESULTS: With a 3-mm depth, suitable access predicted 84% patients with 4, 31% cases ( P <0.001). improved 5-mm depth: 97% 65% When comparing 3- sinus sequestration lowest (13% versus 2%; <0.001), highest (61% 32%; CONCLUSIONS: redo-TAVR relates position Evolut, native annular anatomy. quantitative analysis may provide useful information inform refine individualized preprocedural planning TAVR guide lifetime management future redo-TAVR. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02701283.

Язык: Английский

---

Outcomes of Transcatheter Aortic Valve Replacement Using Third-Generation Balloon-Expandable Versus Self-Expanding Valves: A Meta-analysis

Journal of the Society for Cardiovascular Angiography & Interventions, Год журнала: 2024, Номер 3(7), С. 102146 - 102146

Опубликована: Май 22, 2024

The choice of transcatheter aortic valve replacement (TAVR) prosthesis is crucial in optimizing short- and long-term outcomes. objective this study was to conduct a meta-analysis comparing outcomes third-generation balloon-expandable valves (BEV) vs self-expanding (SEV).

Язык: Английский

---

Reinterventions After CoreValve/Evolut Transcatheter or Surgical Aortic Valve Replacement for Treatment of Severe Aortic Stenosis

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Год журнала: 2024, Номер 17(8), С. 1007 - 1016

Опубликована: Апрель 1, 2024

Язык: Английский

---

Use and performance of the evolut FX transcatheter aortic valve system

Cardiovascular revascularization medicine, Год журнала: 2024, Номер 67, С. 1 - 7

Опубликована: Апрель 7, 2024

Язык: Английский

---

Decreasing pacemaker implantation rates with Evolut supra-annular transcatheter aortic valves in a large real-world registry

Cardiovascular revascularization medicine, Год журнала: 2024, Номер 69, С. 1 - 9

Опубликована: Май 20, 2024

Язык: Английский

---